HemaSeq Dx – Diagnostic kit for hematooncology (Q11306): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): It is a multidisciplinary highly innovative project aimed at developing diagnostic kits for the detection of clinically relevant mutations in chronic lymphocytic leukemia and multiple myeloma, including development of evaluation software for clinical evaluation of mutations. The aim of this industrial development and research is a product of a high degree of specificity and innovation using a new generation sequencing technique with features tha...) |
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
||
| description / en | description / en | ||
Project in Czech Republic | Project Q11306 in Czech Republic | ||
| description / cs | description / cs | ||
Projekt v | Projekt Q11306 v Czechia | ||
Revision as of 15:43, 28 October 2020
Project Q11306 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HemaSeq Dx – Diagnostic kit for hematooncology |
Project Q11306 in Czech Republic |
Statements
29,985,600.0 Czech koruna
0 references
48,000,000.0 Czech koruna
0 references
62.47 percent
0 references
1 January 2018
0 references
19 April 2020
0 references
Institute of Applied Biotechnologies a.s.
0 references
50°5'1.93"N, 14°30'28.48"E
0 references
10800
0 references
Jedná se o multidisciplinární vysoce inovativní projekt zaměřený na vývoj diagnostických souprav pro detekci klinicky relevantních mutací u chronické lymfocytární leukemie a mnohočetného myelomu, včetně vývoje vyhodnocovacího softwaru pro klinické vyhodnocení mutací. Cílem tohoto průmyslového vývoje a výzkumu je produkt vysoké míry specifičnosti a inovativnosti využívající techniku sekvenování nové generace s vlastnostmi, které současný trh nenabízí. a. (Czech)
0 references
It is a multidisciplinary highly innovative project aimed at developing diagnostic kits for the detection of clinically relevant mutations in chronic lymphocytic leukemia and multiple myeloma, including development of evaluation software for clinical evaluation of mutations. The aim of this industrial development and research is a product of a high degree of specificity and innovation using a new generation sequencing technique with features that the current market does not offer. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_084/0010310
0 references